ArticleDiscover oncology2025
Modulation of the tumor microenvironment by zerumbone and 5-fluorouracil in colorectal cancer by target in cancer-associated fibroblasts.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- In vitro evaluation of the Anticarcinogenic effects of zerumbone in the SK-UT-1 human uterine Leiomyosarcoma cell line.Molecular biology reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis research aimed at the evaluation of the incremental effect(s) of combination therapy on colorectal cancer-associated fibroblasts (CAFs) in vivo and in vitro models of CRC. Drug resistance decreases the effectiveness of treatment for colorectal cancer (CRC) patients. CAFs, the main cells in the tumor stroma, contribute essentially to cancer drug resistance. Zerumbone (ZER) has been used for its anti-tumorigenic feature in various cancers. Also, 5-fluorouracil (5-FU) resistance is widely reported in advanced CRC patients. The possible impacts of combination therapy (or polytherapy is therapy that uses more than one medication or modality) with the use of herbs combined with chemical medicines may lead to improvement in patients' responses.
methodsAccording to the research design, the influence of 5-FU and ZER on the viability of the CT-26 cell line was examined through the MTT assay, and the size and dimension of the tumors were measured after 21 days of therapy in CRC BALB/c mice, and then the CAF cells were separated from the tissues of the tumors. Genes' mRNA expression and also the level of the proteins of the genes of interest (Survivin, Vimentin, & β -catenin) were evaluated using qRT-PCR and Western blotting on CT-26 and mouse-isolated CAF cells. RESULTS AND
conclusionsWe showed that ZER and 5-FU significantly increased our gene expression in the CT-26 cell line and isolated CAFs in the level of protein and mRNA in comparison to the controls (ZER-treated, untreated, & 5-FU-treated). Moreover, evaluating the size of the tumor in ZER and 5-FU-treated groups demonstrated a remarkable decline, which exhibited higher prominence in the group of combination therapy. A combination of natural and chemical drugs can largely enhance the effectiveness of cancer therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.